Anchor Capital Advisors LLC Sells 3,007 Shares of Astrazeneca Plc $AZN

Anchor Capital Advisors LLC reduced its stake in Astrazeneca Plc (NYSE:AZN) by 2.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 111,343 shares of the company’s stock after selling 3,007 shares during the period. Anchor Capital Advisors LLC’s holdings in Astrazeneca were worth $19,541,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. CIBC Asset Management Inc increased its stake in shares of Astrazeneca by 3.7% in the fourth quarter. CIBC Asset Management Inc now owns 253,856 shares of the company’s stock valued at $44,552,000 after buying an additional 9,132 shares in the last quarter. Marble Wealth LLC bought a new position in Astrazeneca in the 4th quarter valued at $586,000. Bank of New York Mellon Corp boosted its position in Astrazeneca by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 1,032,000 shares of the company’s stock valued at $181,116,000 after buying an additional 25,833 shares during the last quarter. Calton & Associates Inc. bought a new position in Astrazeneca in the 4th quarter valued at $412,000. Finally, Channing Global Advisors LLC boosted its position in Astrazeneca by 5.8% in the 4th quarter. Channing Global Advisors LLC now owns 10,682 shares of the company’s stock valued at $1,875,000 after buying an additional 590 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Weiss Ratings assumed coverage on Astrazeneca in a research report on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. UBS Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research report on Monday. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Stock Performance

AZN opened at $177.34 on Wednesday. The business’s 50-day moving average price is $191.20 and its two-hundred day moving average price is $184.28. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The company has a market capitalization of $275.04 billion, a price-to-earnings ratio of 26.63, a P/E/G ratio of 1.43 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Equities analysts expect that Astrazeneca Plc will post 10.26 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.